

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Evaluation of comparative effect of intravitreal bevasizumab on visual acuity and central macular thickness in patient with central serous chorioretinopathy

Protocol summary

Summary

Comparative effectiveness of intravitreal injection of bevacizumab on visual acuity and central macular thickness in patients with central serous chorioretinopathy , Inclusion criteria: Patients with visual loss (2 lines Snellen chart or more) and in scan (central macular thickness greater than 250 microns) Central serous chorioretinopathy diagnosis has been laid for them. Exclusion criteria: Patients with adequate visual loss with pathological retinal diseases other than Central serous retinopathy and diabetic retinopathy and hypertensive retinopathy and retinal dystrophies and patients who do not have the desire to enter the study. The study population:patients with Central serous chorioretinopathy referred to Alzahra eye hospital The sample volume:30 patients with Central serous chorioretinopathy . Intervention:intravitreal injection of 1.25 mg bevacizumab after the diagnosis Primary consequences :changes in visual acuity and central macular thickness

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2017041533448N1**

Registration date: **2017-05-24, 1396/03/03**

Registration timing: **prospective**

Last update:

Update count: **0**

Registration date

2017-05-24, 1396/03/03

Registrant information

Name

Seyed Sajad Ahmadi

Name of organization / entity

Alzahra Eye Hospital

Country

Iran (Islamic Republic of)

Phone

+98 54 3323 3551

Email address

dr.sajadahmadi@zaums.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice chancellor for research, Zahedan University of Medical Sciences

Expected recruitment start date

2017-05-31, 1396/03/10

Expected recruitment end date

2017-09-01, 1396/06/10

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of comparative effect of intravitreal bevasizumab on visual acuity and central macular thickness in patient with central serous chorioretinopathy

Public title

Evaluation of treatment options of central serous chorioretinopathy

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Patients with visual loss (2 lines Snellen chart or more) and in scan (the thickness of the central part of the macula greater than 250 microns) diagnosis

of central serous chorioretinopathy they laid is. Exclusion criteria: Patient with visual loss with pathological retinal diseases other than Central serous retinopathy and diabetic retinopathy and hypertensive retinopathy and retinal dystrophies and patients who do not have the desire to enter the study.

Age

No age limit

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: 30

Randomization (investigator's opinion)

Randomized

Randomization description**Blinding (investigator's opinion)**

Double blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee of Zahedan University of Medical Science

Street address

Dr.Hesabi Squire

City

Zahedan

Postal code

98167-43463

Approval date

2017-03-07, 1395/12/17

Ethics committee reference number

IR. ZAUMS. REC.1395.109

Health conditions studied**1****Description of health condition studied**

Central Serous Chorioretinopathy

ICD-10 code

H35.7

ICD-10 code description

Central Serous Chorioretinopathy

Primary outcomes**1****Description**

Visual acuity

Timepoint

Before start the study and 2 months and 4 months after intervention

Method of measurement

Snellen acuity chart

Secondary outcomes**1****Description**

Central Macular Thickness

Timepoint

Before start the study and 2 months and 4 months after intervention

Method of measurement

Optical Coherence Tomography

Intervention groups**1****Description**

Control group : without any intervention , just close observation (15 patients)

Category

Diagnosis

2**Description**

Intervention group : 1.25 mg intravitreal injection of bevasizumab , one time intravitreal injection (15 patients)

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Alzahra Eye Hospital Zahedan

Full name of responsible person

Seyed Sajad Ahmadi

Street address

Shahid Mottahari St , Zahedan

City

Zahedan

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice chancellor for research, Zahedan University of Medical Sciences

Full name of responsible person

Mohammad Reza Shahraki

Street address

Dr.Hesabi Squire

City

Zahedan

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Vice chancellor for research, Zahedan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Person responsible for general inquiries

Contact**Name of organization / entity**

Vice chancellor for research, Zahedan University of Medical Sciences

Full name of responsible person

Mohammad Reza Shahraki

Position

Physiologist , Phd, Vice chancellor for research, Zahedan University of Medical Sciences

Other areas of specialty/work**Street address**

Dr .Hesabi Squire , Zahedan

City

Zahedan

Postal code**Phone**

+98 54 3329 5725

Fax**Email**

m_Shahrakim@zaums.ac.ir

Web page address

Person responsible for scientific inquiries

Contact**Name of organization / entity**

Alzahra Eye Hospital Zahedan

Full name of responsible person

Alireza Maleki

Position

Vitreoretinal Fellowship , Associated Proffesor

Other areas of specialty/work**Street address**

Shahid Mottahari St , Zahedan

City

Zahedan

Postal code**Phone**

+98 543233551

Fax**Email**

a_r_maleki@yahoo.com

Web page address

Person responsible for updating data

Contact**Name of organization / entity**

Alzahra Eye Hospital Zahedan

Full name of responsible person

Seyed Sajad Ahmadi

Position

Ophthalmology Resident

Other areas of specialty/work**Street address**

Shahid Mottahari St , Zahedan

City

Zahedan

Postal code**Phone**

+98 543233551

Fax**Email**

dr.sajadahmadi@zaums.ac.ir

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty